Department of Health and Human Services 2013 – Federal Register Recent Federal Regulation Documents

Results 1,151 - 1,200 of 3,929
National Institute on Aging; Notice of Closed Meetings
Document Number: 2013-23232
Type: Notice
Date: 2013-09-25
Agency: Department of Health and Human Services, National Institutes of Health
Government-Owned Inventions; Availability for Licensing
Document Number: 2013-23231
Type: Notice
Date: 2013-09-25
Agency: Department of Health and Human Services, National Institutes of Health
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Center for Scientific Review; Notice of Closed Meetings
Document Number: 2013-23211
Type: Notice
Date: 2013-09-25
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of General Medical Sciences; Notice of Closed Meeting
Document Number: 2013-23210
Type: Notice
Date: 2013-09-25
Agency: Department of Health and Human Services, National Institutes of Health
National Institute on Deafness and Other Communication Disorders; Notice of Meeting
Document Number: 2013-23209
Type: Notice
Date: 2013-09-25
Agency: Department of Health and Human Services, National Institutes of Health
Request for Information: The National Toxicology Program Requests Information on Use, Human Exposure, and Toxicity of Vinpocetine
Document Number: 2013-23212
Type: Notice
Date: 2013-09-24
Agency: Department of Health and Human Services, National Institutes of Health
To facilitate the design of toxicological studies for vinpocetine (CAS RN: 42971-09-5), the National Toxicology Program (NTP) at the National Institute of Environmental Health Sciences (NIEHS) requests the submission of available information regarding (1) exposure, pharmacokinetics, toxicity, safety, or efficacy in humans; (2) production, use, and consumption patterns in the United States; (3) genotoxicity, repeated dose toxicity, prenatal developmental toxicity, reproductive toxicity, chronic toxicity, and carcinogenicity studies in experimental animals; and (4) any other information relative to the safety or toxicity of vinpocetine not listed above.
Agency Recordkeeping/Reporting Requirements Under Emergency
Document Number: 2013-23188
Type: Notice
Date: 2013-09-24
Agency: Department of Health and Human Services, Administration for Children and Families
Agency Information Collection Activities; Proposed Collection; Public Comment Request
Document Number: 2013-23176
Type: Notice
Date: 2013-09-24
Agency: Department of Health and Human Services, Office of the Secretary
In compliance with section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, announces plans to submit a new Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting that ICR to OMB, OS seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
National Standards for Culturally and Linguistically Appropriate Services (CLAS) in Health and Health Care
Document Number: 2013-23164
Type: Notice
Date: 2013-09-24
Agency: Department of Health and Human Services
The Department of Health and Human Service (HHS), Office of the Secretary, Office of Minority Health (OMH) announces the publication of the final enhanced National Standards for Culturally and Linguistically Appropriate Services (CLAS) in Health and Health Care, known as the enhanced National CLAS Standards. In developing the enhanced National CLAS Standards, OMH undertook the National CLAS Standards Enhancement Initiative. From 2010-2012, this initiative included input from a National Project Advisory Committee composed of subject matter experts representing public, private and government sectors, regional public meetings, public comment period, and a systematic literature review. The enhanced National CLAS Standards, including a brief background summary of the development process and public comment period, are printed below.
Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH)
Document Number: 2013-23135
Type: Notice
Date: 2013-09-24
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting
Document Number: 2013-23083
Type: Notice
Date: 2013-09-24
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Document Number: 2013-23082
Type: Notice
Date: 2013-09-24
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Amended Notice of Meeting
Document Number: 2013-23081
Type: Notice
Date: 2013-09-24
Agency: Department of Health and Human Services, National Institutes of Health
State System Development Initiative (SSDI) Grant Program; Single-Case Deviation From Competition Requirements
Document Number: 2013-23074
Type: Notice
Date: 2013-09-24
Agency: Health Resources and Services Administration, Department of Health and Human Services, Department of Health & Human Services
HRSA will be issuing a non-competitive program expansion supplement for one State SSDI Grant. Approximately $82,332 in supplemental funding will be made available in the form of a grant to the Department of Health Care Services, Sacramento, California, Grant Number H18MC24474, during the budget period of December 1, 2012, through November 30, 2013. The SSDI Grant program, CFDA No. 93.110, is authorized by Title V, Social Security Act, Section 501(a)(2); as amended (42 U.S.C. 701(a)(2)). The SSDI Grant program was developed to complement the Title V MCH Services Block Grant program by assisting state MCH and Children with Special Health Care Needs (CSHCN) programs in the building of state data capacity and infrastructure that support comprehensive, community- based systems of care for all children and their families. SSDI grants to states are intended to not only advance and strengthen data capacity by directing grant resources towards Title V MCH Block Grant program's Health Systems Capacity Indicator (HSCI) 09A (i.e., the ability of states to assure that the MCH programs and Title V agency have access to policy and program relevant information and data), but also to move states forward in developing improved capacity for reporting standardized and quality data that is timely.
Unique Device Identification System
Document Number: 2013-23059
Type: Rule
Date: 2013-09-24
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is issuing a final rule to establish a system to adequately identify devices through distribution and use. This rule requires the label of medical devices to include a unique device identifier (UDI), except where the rule provides for an exception or alternative placement. The labeler must submit product information concerning devices to FDA's Global Unique Device Identification Database (GUDID), unless subject to an exception or alternative. The system established by this rule requires the label and device package of each medical device to include a UDI and requires that each UDI be provided in a plain-text version and in a form that uses automatic identification and data capture (AIDC) technology. The UDI will be required to be directly marked on the device itself if the device is intended to be used more than once and intended to be reprocessed before each use.
Global Unique Device Identification Database; Draft Guidance for Industry; Availability
Document Number: 2013-23058
Type: Notice
Date: 2013-09-24
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of the draft guidance entitled ``Global Unique Device Identification Database (GUDID).'' FDA is issuing this draft guidance to communicate our current thinking of how the GUDID will operate. The guidance includes both information about how device labelers (in most instances, the device manufacturer) will interface with the GUDID, as well as information on the database elements that must be submitted to the GUDID and their definitions. We intend to publish a final guidance after the close of the comment period and our implementation of the GUDID.
Submission for OMB Review; 30-day Comment Request: The Framingham Heart Study (FHS)
Document Number: 2013-23060
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, National Institutes of Health
Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. This proposed information collection was previously published in the Federal Register on May 7, 2013, pages 26639-41 and allowed 60-days for public comment. No public comments were received. The National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number. Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, OIRA_submission@omb.eop.gov or by fax to 202-395-6974, Attention: NIH Desk Officer. Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.
Agency Information Collection Activities: Submission for OMB Review; Comment Request
Document Number: 2013-23053
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; Notice of Meeting
Document Number: 2013-23022
Type: Notice
Date: 2013-09-23
Agency: Food and Drug Administration, Department of Health and Human Services
Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; Notice of Meeting
Document Number: 2013-23021
Type: Notice
Date: 2013-09-23
Agency: Food and Drug Administration, Department of Health and Human Services
Clinical Trial Design for Intravenous Fat Emulsion Products; Public Workshop
Document Number: 2013-23020
Type: Notice
Date: 2013-09-23
Agency: Food and Drug Administration, Department of Health and Human Services
Fibromyalgia Public Meeting on Patient-Focused Drug Development
Document Number: 2013-23019
Type: Notice
Date: 2013-09-23
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing a public meeting and an opportunity for public comment on Patient-Focused Drug Development for fibromyalgia. Patient-Focused Drug Development is part of FDA's performance commitments in the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). The public meeting is intended to allow FDA to obtain patients' perspectives on the impact of fibromyalgia on daily life as well as the available therapies for fibromyalgia.
Submission for OMB Review; Comment Request
Document Number: 2013-22996
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, Administration for Children and Families
Submission for OMB Review; Comment Request
Document Number: 2013-22995
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, Administration for Children and Families
Federal Tort Claims Act (FTCA) Medical Malpractice Program Regulations: Clarification of FTCA Coverage for Services Provided to Non-Health Center Patients
Document Number: 2013-22993
Type: Rule
Date: 2013-09-23
Agency: Department of Health and Human Services
This final rule amends the current regulatory text of the regulations for FTCA Coverage of Certain Grantees and Individuals with the key text and examples of activities that have been determined, consistent with provisions of the existing regulation, to be covered by the FTCA, as previously published in the September 25, 1995 Federal Register Notice (September 1995 Notice). Additionally, HRSA has added examples of services covered under the FTCA involving individual emergency care provided to a non-health center patient and updated the September 1995 Notice immunization example to include events to immunize individuals against infectious illnesses. The amended regulation will supersede the September 1995 Notice.
National Institute on Drug Abuse; Notice of Closed Meetings
Document Number: 2013-22992
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting
Document Number: 2013-22991
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, National Institutes of Health
National Cancer Institute; Amended Notice of Meeting
Document Number: 2013-22990
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services
Center for Scientific Review; Notice of Closed Meetings
Document Number: 2013-22989
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
Document Number: 2013-22988
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings
Document Number: 2013-22987
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Document Number: 2013-22986
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Meeting
Document Number: 2013-22985
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings
Document Number: 2013-22984
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Document Number: 2013-22983
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, National Institutes of Health
National Cancer Institute; Amended Notice of Meeting
Document Number: 2013-22982
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services
National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting
Document Number: 2013-22981
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, National Institutes of Health
Proposed Information Collection Activity; Comment Request
Document Number: 2013-22961
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, Administration for Children and Families
Complex Issues in Developing Medical Devices for Pediatric Patients Affected by Rare Diseases; Public Workshop; Request for Comments
Document Number: 2013-22960
Type: Notice
Date: 2013-09-23
Agency: Food and Drug Administration, Department of Health and Human Services
Complex Issues in Developing Drug and Biological Products for Rare Diseases; Public Workshop; Request for Comments
Document Number: 2013-22959
Type: Notice
Date: 2013-09-23
Agency: Food and Drug Administration, Department of Health and Human Services
Agency Information Collection Activities: Submission for OMB Review; Comment Request
Document Number: 2013-22958
Type: Notice
Date: 2013-09-23
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
Statement of Organization, Functions, and Delegations of Authority
Document Number: 2013-22909
Type: Notice
Date: 2013-09-23
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Statement of Organization, Functions, and Delegations of Authority
Document Number: 2013-22908
Type: Notice
Date: 2013-09-23
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Medicare Program; Prospective Payment System for Federally Qualified Health Centers; Changes to Contracting Policies for Rural Health Clinics; and Changes to Clinical Laboratory Improvement Amendments of 1988 Enforcement Actions for Proficiency Testing Referral
Document Number: 2013-22821
Type: Proposed Rule
Date: 2013-09-23
Agency: Centers for Medicare & Medicaid Services, Department of Health and Human Services
This proposed rule would establish methodology and payment rates for a prospective payment system (PPS) for federally qualified health center (FQHC) services under Medicare Part B beginning on October 1, 2014, in compliance with the statutory requirement of the Affordable Care Act. This proposed rule would also establish a policy which would allow rural health clinics (RHCs) to contract with nonphysician practitioners when statutory requirements for employment of nurse practitioners and physician assistants are met, and make other technical and conforming changes to the RHC and FQHC regulations. Finally, this proposed rule would make changes to the Clinical Laboratory Improvement Amendments (CLIA) regulations regarding enforcement actions for proficiency testing referral.
Tribal Consultation Meeting
Document Number: 2013-22950
Type: Notice
Date: 2013-09-20
Agency: Department of Health and Human Services, Administration for Children and Families
Pursuant to the Improving Head Start for School Readiness Act of 2007, Public Law 110-134, notice is hereby given of two 1-day Tribal Consultation Sessions to be held between the Department of Health and Human Services, Administration for Children and Families, Office of Head Start leadership and the leadership of Tribal Governments operating Head Start (including Early Head Start) programs. The purpose of these Consultation Sessions is to discuss ways to better meet the needs of American Indian and Alaska Native children and their families, taking into consideration funding allocations, distribution formulas, and other issues affecting the delivery of Head Start services in their geographic locations [42 U.S.C. 9835, 640(l)(4)].
Draft NIH Genomic Data Sharing Policy Request for Public Comments
Document Number: 2013-22941
Type: Notice
Date: 2013-09-20
Agency: Department of Health and Human Services, National Institutes of Health
The National Institutes of Health (NIH) is seeking public comments on the draft Genomic Data Sharing (GDS) Policy that promotes sharing, for research purposes, of large-scale human and nonhuman genomic \1\ data generated from NIH-supported and NIH-conducted research.
Medicare Program; Obtaining Final Medicare Secondary Payer Conditional Payment Amounts via Web Portal
Document Number: 2013-22934
Type: Rule
Date: 2013-09-20
Agency: Centers for Medicare & Medicaid Services, Department of Health and Human Services
This interim final rule with comment period specifies the process and timeline for expanding CMS' existing Medicare Secondary Payer (MSP) Web portal to conform to section 201 of the Medicare IVIG and Strengthening Medicare and Repaying Taxpayers Act of 2012 (the SMART Act). The interim final rule specifies a timeline for developing a multifactor authentication solution to securely permit authorized users other than the beneficiary to access CMS' MSP conditional payment amounts and claims detail information via the MSP Web portal. It also requires that we add functionality to the existing MSP Web portal that permits users to: notify us that the specified case is approaching settlement; obtain time and date stamped final conditional payment summary forms and amounts before reaching settlement; and ensure that relatedness disputes and any other discrepancies are addressed within 11 business days of receipt of dispute documentation.
National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings
Document Number: 2013-22891
Type: Notice
Date: 2013-09-20
Agency: Department of Health and Human Services, National Institutes of Health
Nominations to the Report on Carcinogens; Request for Information
Document Number: 2013-22890
Type: Notice
Date: 2013-09-20
Agency: Department of Health and Human Services, National Institutes of Health
National Toxicology Program (NTP) Office of the Report on Carcinogens (ORoC) requests information on 20 substances, mixtures, and exposure circumstances (collectively referred to as ``substances'') nominated for possible review for future editions of the Report on Carcinogens (RoC).
Prospective Grant of Exclusive Patent License: Oral Treatment of Hemophilia
Document Number: 2013-22875
Type: Notice
Date: 2013-09-20
Agency: Department of Health and Human Services, National Institutes of Health
This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 404, that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an Exclusive Patent License to ProGenetics, LLC, a company having its headquarters in Blacksburg, Virginia, to practice the inventions embodied in U.S. Patent No. 7,220,718, issued 27 February 2007 (HHS Ref. No. E-281-2001/ 0-US-03]), European Patent Application No. 02756904.5 (HHS Ref. No. E281-2001/0-EP-04), filed August 2, 2002, and U.S. Patent No. 7,867,974, issued 11 January 2011 (HHS Ref. No. E-281-2001/0-US-05), entitled respectively, ``Oral Treatment of Hemophilia'' and ``Induction of Tolerance by Oral administration of Factor VIII and Treatment of Hemophilia''. The patent rights in these inventions have been assigned to or exclusively licensed to the Government of the United States of America. The prospective Exclusive Patent License territory may be ``worldwide'', and the field of use may be limited to: ``Treatment of Hemophilia A and B and immunotolerization using oral delivery methods''.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.